公开(公告)号：US20240360183A1

公开(公告)日：2024-10-31

申请号：US18605501

申请日：2024-03-14

申请人： Shanghai Puyou Biomedical Co., Ltd.

发明人： Yinghao Zhang ,  Guirui Yan ,  Yao Wang ,  Wenhan Li

IPC分类号： C07K14/245 ,  A61K9/00 ,  A61K38/00 ,  A61P27/04

CPC分类号： C07K14/245 ,  A61K9/0048 ,  A61P27/04 ,  A61K38/00

摘要： The present disclosure provides a novel polypeptide. Also provided is an ophthalmic composition for treating or preventing dry eye (DE) or DE associated disorders. Also provided is a method for treating or preventing DE or DE associated disorders, stimulating tears, stabilizing tear film or any combination thereof in a subject in need thereof, comprising administering to the subject an effective amount of the novel peptides. Also provided is a contact lenses care product comprising the novel peptides and the preparation method thereof.

公开(公告)号：US12128010B2

公开(公告)日：2024-10-29

申请号：US17833836

申请日：2022-06-06

申请人： NOVALIQ GMBH

发明人： Dieter Scherer ,  Ralf Grillenberger ,  Frank Löscher ,  Hartmut Voss

IPC分类号： A61K31/02 ,  A61F9/00 ,  A61K9/00 ,  A61K9/08 ,  A61P27/02

CPC分类号： A61K31/02 ,  A61F9/0008 ,  A61K9/0048 ,  A61K9/08 ,  A61P27/02

摘要： The present invention is directed to compositions comprising semifluorinated compounds and their use as medicaments for topical administration to the eye.

公开(公告)号：US20240350402A1

公开(公告)日：2024-10-24

申请号：US18687993

申请日：2022-08-30

申请人： The Cleveland Clinic Foundation

发明人： Steven E. WILSON

IPC分类号： A61K9/00 ,  A61K9/06 ,  A61K31/4178 ,  A61K31/573 ,  A61P27/02

CPC分类号： A61K9/0048 ,  A61K9/0051 ,  A61K9/06 ,  A61K31/4178 ,  A61K31/573 ,  A61P27/02

摘要： The present invention relates to compositions, systems, and methods for treating a subject with a corneal injury and/or an existing corneal scar using a composition comprising an ACE-2 receptor antagonist (e.g., losartan, telmisartan, valsartan, olmesartan, candesartan, irbesartan, eprosartan, azilsartan, or losartan metabolite EXP3174). In certain embodiments, the ACE-2 receptor antagonist is present in the composition at a concentration of about 0.2 mg/ml to 0.9 mg/ml or about 0.1 mg/ml to 2.0 mg/ml.

公开(公告)号：US20240342174A1

公开(公告)日：2024-10-17

申请号：US18597497

申请日：2024-03-06

申请人： Bausch + Lomb Ireland Limited

发明人： Quintus MEDLEY ,  Muneto MOGI ,  Michela MONTECCHI-PALMER ,  Kalliopi STASI

IPC分类号： A61K31/517 ,  A61K9/00

CPC分类号： A61K31/517 ,  A61K9/0048

摘要： The present invention provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.

公开(公告)号：US20240342080A1

公开(公告)日：2024-10-17

申请号：US18290749

申请日：2022-07-20

申请人： Sanford Burnham Prebys Medical Discovery Institute

发明人： Francesca M. MARASSI ,  Kyungsoo SHIN ,  James E. KENT

IPC分类号： A61K9/00 ,  C07K16/18

CPC分类号： A61K9/0048 ,  C07K16/18

摘要： A method for inhibiting activity of a human blood protein vitronectin is disclosed. The method includes administering a composition that inhibits activity of a calcium and hydroxyapatite binding site of the human blood protein vitronectin. An ophthalmic composition is also disclosed. The composition includes: an effective amount of an organic compound having a molecular weight of less than 1,000 Daltons; and one or more selected from the group consisting of a thickening agent, a pH adjustor, a wetting agent, a stabilizer, a solubilize, a preservative, a refreshing agent, and an ointment base.

公开(公告)号：US12115245B2

公开(公告)日：2024-10-15

申请号：US17461086

申请日：2021-08-30

申请人： Xiamen University

发明人： Cheng Li ,  Mengyi Jin ,  Ying Hong ,  Zuguo Liu

IPC分类号： A61K9/00 ,  A61F9/007 ,  A61K9/08 ,  A61K31/198 ,  A61K47/02 ,  A61K47/12

CPC分类号： A61K9/0048 ,  A61F9/007 ,  A61K9/08 ,  A61K31/198 ,  A61K47/02 ,  A61K47/12 ,  A61B2217/007

摘要： An anterior chamber perfusate for intraocular surgery and its use. The anterior chamber perfusate not only balances intraocular pressure, but also contains a certain amount of L-alanyl-L-glutamine (Ala-Gln).

公开(公告)号：US12102628B2

公开(公告)日：2024-10-01

申请号：US17706225

申请日：2022-03-28

申请人： Seinda Pharmaceutical Guangzhou Corporation

发明人： Hui Ouyang ,  Yong Qiu

IPC分类号： A61P27/02 ,  A61K9/00 ,  A61K31/06 ,  A61K31/216 ,  A61K31/222 ,  A61K31/24 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/439 ,  A61K31/4406 ,  A61K31/46 ,  A61K31/498 ,  A61K31/551 ,  A61K31/5513 ,  A61P27/10 ,  C07C217/20 ,  C07C219/10 ,  C07D213/04 ,  C07D235/02 ,  C07D403/04 ,  C07D403/12 ,  C07D471/08 ,  C07D487/04 ,  C07D491/18

CPC分类号： A61K31/46 ,  A61K9/0048 ,  A61K31/24 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/498 ,  A61K31/551 ,  A61P27/10

摘要： Compositions and methods useful in slowing, inhibiting, or regressing the progression of myopia, while minimizing pupil dilation and light sensitivity are provided herein. Provided compositions can include a muscarinic receptor antagonist and a miotic agent.

公开(公告)号：US20240316219A1

公开(公告)日：2024-09-26

申请号：US18558919

申请日：2022-05-02

申请人： NORTH CAROLINA STATE UNIVERSITY ,  THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

发明人： Brian Gilger ,  Elizabeth Crabtree ,  Matthew L. Hirsch

IPC分类号： A61K48/00 ,  A61K9/00 ,  A61P27/02 ,  C07K14/54 ,  C12N15/86

CPC分类号： A61K48/005 ,  A61K9/0048 ,  A61K48/0075 ,  A61P27/02 ,  C07K14/5428 ,  C12N15/86 ,  C12N2750/14143

摘要： The present disclosure provides compositions and methods related to the treatment of ocular diseases in equines. In particular, the present disclosure provides novel compositions and methods related to the administration of therapeutic compositions comprising AAV-equine IL-10 for the treatment and/or prevention of various ocular diseases (e.g., non-infectious uveitis).

公开(公告)号：US20240316039A1

公开(公告)日：2024-09-26

申请号：US18259982

申请日：2022-01-13

申请人： SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED

发明人： Ajay Jaysingh KHOPADE ,  Arindam HALDER

IPC分类号： A61K31/498 ,  A61K9/00 ,  A61K9/10 ,  A61P27/06

CPC分类号： A61K31/498 ,  A61K9/0048 ,  A61K9/10 ,  A61P27/06

摘要： The present invention relates to a method of reducing elevated intraocular pressure in humans with open angle glaucoma or ocular hypertension, comprising administering brimonidine or its pharmaceutically acceptable salt. The invention also relates to a pharmaceutical composition suitable for ophthalmic use comprising brimonidine or its pharmaceutically acceptable salt.

公开(公告)号：US12097209B2

公开(公告)日：2024-09-24

申请号：US17624311

申请日：2020-06-30

申请人： Oculis Operations Sàrl

发明人： Thorsteinn Loftsson ,  Zoltán Fülöp

IPC分类号： A61K31/573 ,  A61K9/00 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/20 ,  A61K47/40 ,  A61P27/02 ,  A61P29/00

CPC分类号： A61K31/573 ,  A61K9/0048 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/20 ,  A61K47/40 ,  A61P27/02 ,  A61P29/00

摘要： A method is described of stabilizing the pH of an aqueous composition including a drug that is prone to oxidation. The method includes adding an additive to prevent oxidation of the drug that is prone to oxidation. Also described, is a method of stabilizing the pH of an aqueous composition including a corticosteroid, the method including adding an additive to prevent oxidation of the corticosteroid. Further, a composition is described that includes a corticosteroid and an additive to prevent oxidation of the corticosteroid.